Video

Dr. Alter Discusses the Immunotherapy Provenge

Dr. Robert Alter from John Theurer Cancer Center Discusses the Immunotherapy Provenge

Robert S. Alter, MD, co-chief, Urologic Oncology, John Theurer Cancer Center, describes the immunotherapy Provenge (sipuleucel-T) as a state-of-the-art breakthrough in the way prostate cancer patients are treated.

Vaccine therapies, such as Provenge, utilize the patient's immune system to fight tumor cells. In comparison to standard chemotherapy and newer targeted therapies Provenge has fewer toxicities and is better tolerated. The drug is a very short coursed therapy that does not subject patients to taking medications on a daily basis, which prevents many of the common toxicities that accompany daily doses of chemotherapy.

Alter describes Provenge as a durable therapy that effectively improves quality-of-life for patients.

Related Videos
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Chirag Shah, MD
Jason A. Mouabbi, MD
Roger Li, MD,
Brian I. Rini, MD, FASCO
Marc-Oliver Grimm, MD
David Samuel Dicapua Siegel, MD
Moritz Fürstenau, MD
Joseph Franses, MD, PhD